High Profile HealthCare Companies: Leading Pharma Company Secures New Patents

Thu Feb 14, 2013 9:11am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link


CORAL SPRINGS, Florida,  February 14, 2013  /PRNewswire/ --

FinancialNewsMedia.com  "Active Health Stocks to Watch" for today:  Crown
Marketing Pharmaceuticals, Amarin Corporation (NASDAQ:  AMRN), Keryx
Biopharmaceuticals Inc. (NASDAQ:  KERX), Eli Lilly and Company (NYSE:  LLY),
Medtronic, Inc. (NYSE:  MDT), RPX Corporation (NASDAQ:  RPXC).

Crown Marketing Pharmaceuticals closed up over 16% in trading yesterday closing
at  $0.128  per share.  Crown Marketing Pharmaceuticals announced today that
Patents for its Controlled Drug Delivery Technology (CDDT) have been approved
and registered in  South Africa.  This is Crown Marketing Pharmaceuticals's
second major announcement regarding the approval of new Patents following last
week's news it had also secured Patents in  Norway.  Crown is continuing to
secure its worldwide patent rights as it pursues novel applications of its drug
delivery technology. Crown Marketing Pharmaceuticals also announced last week on
 February 7th  the company has begun to review positive in vivo test results by
examining blood plasma levels in test subjects using Crown's Controlled Drug
Delivery Technology (CDDT). A clinical trial was conducted using 300 mg of
Dexibuprofren Lysine and found that the blood plasma levels tracked the in vitro
test results conducted earlier. The clinical trial appears to validate our
belief and claims that because of the controllable diffusion dynamics and our
mathematical modeling, we can predict with a high degree of certainty the
release kinetics. For more details regarding Crown's CDDT applications, go to 

Stay informed on Crown Marketing developments by getting  FREE news alerts  &
updates delivered directly to your mobile phone by texting  STOCK  to  545454 
from your cellular device or visit  http://cwnm.mobi  for more details.

Amarin Corporation plc (NASDAQ:  AMRN) closed up in trading yesterday closing at
 $8.58  per share on 2.84Million shares.  AMRN is a biopharmaceutical company
focused on the commercialization and development of therapeutics to improve
cardiovascular health, that announced this week that the United States Patent
and Trademark Office (USPTO) has published notification of Notice of Allowance
for U.S. Patent Application Serial Number 13/614,129. This application includes
claims intended to protect the Vascepa (icosapent ethyl) indication approved by
the U.S. Food and Drug Administration (FDA) based on Amarin's MARINE clinical
trial results.

Keryx Biopharmaceuticals, Inc. (NASDAQ:  KERX) closed up slightly in trading
yesterday closing at  $7.11  per share on 5.47Million shares.  KERX is focused
on the acquisition, development and commercialization of medically important
pharmaceutical products for the treatment of renal disease. Keryx is developing
Zerenex (ferric citrate), an oral, ferric iron-based compound that has the
capacity to bind to phosphate and form non-absorbable complexes. Zerenex has
completed a U.S.-based Phase 3 clinical program for the treatment of
hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal
disease, conducted pursuant to a Special Protocol Assessment (SPA) agreement
with the FDA, and Keryx expects to submit an NDA with the FDA and a MAA with the
EMA in the second quarter of 2013.

Eli Lilly and Company (NYSE:  LLY) closed up slightly in trading yesterday
closing at  $53.44  per share on 4.38Million shares.  An announcement was issued
after the close yesterday that LLY has entered into a master collaboration
agreement with QIAGEN (NASDAQ: QGEN) for the development and commercialization
of companion diagnostics for pairing with Lilly investigational and approved
medicines across all therapeutic areas. The agreement builds on QIAGEN and
Lilly's past work together. Companion diagnostics unlock a patient's molecular
information in order to guide treatment decisions for specific cancers or other
diseases. Financial terms of the agreement are not being disclosed.

Medtronic, Inc. (NYSE:  MDT) closed down slightly in trading yesterday closing
at  $46.99  per share on 3.04Million shares, but was up in After-Market trading.
 MDT announced after the markets closed on Wednesday that it has received Food
and Drug Administration (FDA) clearance for its AIRvance(TM) Bone Screw System
that allows surgeons to perform a hyoid suspension procedure independently or in
combination with other procedures for the treatment of obstructive sleep apnea
(OSA). Under the previous FDA clearance the hyoid suspension procedure was
indicated as an adjunct to the tongue suspension procedure. This latest FDA
clearance makes the AIRvance System the only combined system available for
performing a hyoid suspension procedure as well a tongue suspension procedure.

RPX Corporation (NASDAQ:  RPXC) closed up over 22% in trading yesterday closing
at  $13.05  pre share on 1.1Million shares.  RPXC is a leading provider of
patent risk management solutions, announced yesterday its financial results for
the fourth quarter and year ended  December 31, 2012.  RPXC Revenue for the
fourth quarter of fiscal 2012 totaled  $51.6 million, up 22% from the prior year
period and Revenue for fiscal 2012 totaled  $197.7 million, up 28% from fiscal
2011.  "RPX reported a solid 2012, capped by a strong fourth quarter with
progress in client growth, patent acquisition activity, and the roll out of our
insurance service," said Chief Executive Officer  John Amster.

Other Healthcare companies to monitor for new developments are Bond
Laboratories, Inc (BNLB), an international provider of innovative and
proprietary nutritional supplements for health conscious consumers; YaFarm
Technologies, Inc. (YFRM) subsidiary, The Integrative Stem Cell Institute
(ISCI), is a premier provider of point-of-care, stem cell-based therapies; and
Bio-Matrix Scientific Group, Inc. (BMSN), a biotechnology company developing
regenerative medicine therapies.

FinancialNewsMedia.com is leading provider of third party publishing & news
dissemination services. If you would like more information regarding our news
coverage solutions, please visit http://www.financialnewsmedia.com for more

DISCLAIMER:  FN Media Group LLC (FNMG) is a third party publisher and news
dissemination service provider, which disseminates electronic information
through multiple online media channels.  FNMG is NOT affiliated in any manner
with any company mentioned herein.  FNMG and its affiliated companies are a news
dissemination and financial marketing solutions provider and are NOT a
registered broker/dealer/analyst/adviser, holds no investment licenses and may
NOT sell, offer to sell or offer to buy any security.  FNMG's market updates,
news alerts and corporate profiles are NOT a solicitation or recommendation to
buy, sell or hold securities.  The material in this release is intended to be
strictly informational and is NEVER to be construed or interpreted as research
material.   All readers are strongly urged to perform research and due diligence
on their own and consult a licensed financial professional before considering
any level of investing in stocks.  The companies that are discussed in this
release may or may not have approved the statements made in this release.  FNMG
is not liable for any investment decisions by its readers or subscribers. 
Investors are cautioned that they may lose all or a portion of their investment
when investing in stocks.


This release contains "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E the Securities
Exchange Act of 1934, as amended and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. "Forward-looking statements" describe future expectations,
plans, results, or strategies and are generally preceded by words such as "may",
"future", "plan" or "planned", "will" or "should", "expected," "anticipates",
"draft", "eventually" or "projected". You are cautioned that such statements are
subject to a multitude of risks and uncertainties that could cause future
circumstances, events, or results to differ materially from those projected in
the forward-looking statements, including the risks that actual results may
differ materially from those projected in the forward-looking statements as a
result of various factors, and other risks identified in a company's annual
report on Form 10-K or 10-KSB and other filings made by such company with the
Securities and Exchange Commission. You should consider these factors in
evaluating the forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this release are
made as of the date hereof and FNMG undertakes no obligation to update such

Contact Information:

Company:  FN Media Group, LLC

Contact email:  editor@financialnewsmedia.com

U.S. Phone: +1-954-345-0611

URL:  http://www.financialnewsmedia.com

SOURCE  FinancialNewsMedia.com

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.